Supernus Pharmaceuticals (SUPN) Change in Acquisitions & Divestments (2011 - 2026)

Supernus Pharmaceuticals has reported Change in Acquisitions & Divestments for 16 years, with the latest figure at $57.7 million in Q2 2026.

• Change in Acquisitions & Divestments for Q2 2026 came in at $57.7 million, down 47.77% year-over-year; the trailing twelve-month figure through Jun 2026 was $624.8 million (up 14.07% YoY), and the FY2025 annual result was $774.5 million, up 55.25% from the prior year.
• Change in Acquisitions & Divestments slipped to $57.7 million in Q2 2026, from $59.2 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $468.6 million in Q3 2025 and troughed at $17.6 million in Q4 2022.
• A 5-year average of $108.4 million and a median of $68.0 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments sank 95.36%; it then jumped 729.88% in 2023.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $17.6 million in 2022, then jumped by 102.87% to $35.6 million in 2023, then surged by 273.5% to $133.0 million in 2024, then slumped by 70.43% to $39.3 million in 2025, then surged by 46.66% to $57.7 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $57.7 million in Q2 2026, $59.2 million in Q1 2026, and $39.3 million in Q4 2025.